Company News

BMA 2023, participation of more than 350 Asian and biopharmaceutical companies

CELLiST announces the latest technology for cell culture and process optimization

Ajinomoto Genexine, a cell culture medium research and manufacturing company, announced that it participated in 

‘Biologics Manufacturing Asia 2023 (BMA 2023)’ held at Marina bay sands, Singapore.

The BMA 2023 conference is an event hosted by IMAPAC, a social enterprise located in Singapore. It is held every year in 

Singapore as a networking venue where experts from companies and academia with a biopharmaceutical industry base in each 

region of Asia gather to share know-how in manufacturing and developing high-quality biopharmaceuticals and vaccines.

This year, which celebrated its 10th anniversary, more than 350 organizations and leading biopharmaceutical industry leaders in 

Asia participated and continued heated discussions.

Major tasks such as <Today’s Challenges and Opportunities in Biomanufacturing> and <Biologics Drug Product Analytics and 

Quality Control> were shared as well as innovation strategies that cover detailed topics of each bio process. In addition, about 60 experts appeared as speakers and shared the latest knowledge, and time was also provided for vaccine manufacturers, research 

institutes, and officials from related organizations to have face-to-face networking.

At this event, Ajinomoto Genexine presented the latest technologies for cell culture and process optimization under the theme of <Advanced technologies for media and process optimization for biologics manufacturing>.

In particular, it attracted attention by demonstrating the excellence of the ‘CELLiST’ cell culture medium developed by Ajinomoto. CELLiST has succeeded in localizing cell culture media and is continuing to develop and manufacture animal cell culture media 

containing high-quality amino acids.

An official said, “Ajinomoto Genexine has been suggesting ways to improve productivity in the domestic and overseas 

bio industry as well as improve antibody quality and reduce costs through the cell culture medium change program 

(Media Switch),” adding, “This BMA 2023 is a collaboration between Ajinomoto Genexine and CELLiST. “It was an opportunity to 

confirm the high visitation rate and interest of bio industry officials from various regions of Asia.”